B2BROKER
4.4.2024 16:08:35 CEST | Business Wire | Press release
The latest major upgrade to B2Core was just released by B2Broker, significantly enhancing the platform's back-office and CRM solutions. The V2.1 upgrade delivers on the highly anticipated savings feature, introduces a new trading platform and PSP integrations, and drastically improves the user experience on the platform. Let’s explore:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404452158/en/
B2Broker, a leading liquidity and technology provider, has just announced the release of a new version of B2Core, its sophisticated CRM and back-office solution. B2Core V2.1 integrates the TradeLocker trading platform inside its ecosystem, adds new PSPs and enhances the existing ones, and upgrades its UI. (Photo: Business Wire)
Polished UI & Peak Performance
Version 2.1 of B2Core brings a new user interface, major functionality improvements, and technical fixes.
- A Withdrawal summary provides comprehensive transfer information that features commissions, exchange rates and the net transaction amount.
- Account creation now enforces minimum deposit settings to maintain consistency in the back-office.
- On the Deposit, Withdraw, and Transfer pages, accounts in selectors are now categorised by type (e.g., Fiat, Coins, MT4, MT5) for easier navigation.
- Platform consistency is guaranteed by the Unified Date Format.
- The old and new UI settings can now be easily switched by users.
Integration with TradeLocker Trading Platform
B2Core introduces TradeLocker, an innovative trading platform seamlessly integrated into the trader's room. This addition enhances the company’s existing suite of integrated platforms, including MetaTrader 4, MetaTrader 5, cTrader and B2Trader, offering brokerages a complex set of trading solutions.
TradeLocker presents a comprehensive suite of powerful trading tools and instruments aiming to cater to a wide spectrum of clients, from novices to seasoned traders. The platform is equipped with versatile features designed to support a variety of trading strategies and preferences, facilitating a seamless and efficient trading experience for brokerage clients.
TradeLocker integrates with TradingView to offer a sophisticated charting capability, granting users access to an extensive array of customisable charts and indicators. The platform provides traders with modern tools to manage risks effectively.
Among its standout features are SL & TP Calculator, On-Chart Trading, One-click Trading, Trailing Stop Loss, and Social Mode, enabling traders to efficiently manage their trades engaging with the market. Users can easily develop or customise bots, signals, indicators, and strategies using the TradeLocker AI at TradeLocker Studio.
Payment Improvements and Integrations
Thanks to the V2.1 B2Core update, users now have more transaction options, and the scope of payment integrations has expanded.
Sqala supports deposits and withdrawals in Brazilian reals (BRL). It is renowned for its simplicity, competitive exchange rates, and a convenient dashboard that provides all the essential data. By including Sqala in its portfolio, B2Broker has increased the range of its solutions and fulfilled the needs of customers worldwide.
Transactions have been streamlined and fortified through several new improvements:
- Within the B2Core environment, BridgerPay provides a better deposit process through an automated data fill-in feature that streamlines transaction processing.
- Praxis configuration has been enhanced to improve transaction security. To comply with diverse regulatory standards, you can now enable clients from various countries to submit specific documents.
- The constructor payment adjustments allow clients to attach documents for deposits and withdrawals, ensuring maximum compliance and record accuracy.
The V2.1 upgrade has also brought back access to 1-2-Pay and WireCustom for deposits and withdrawals to expand the choices for transfers.
Engage Customers with Savings Feature
Last but not least, V2.1 adds a savings feature that lets users invest idle funds and get interest over specific periods. The savings programs currently support fixed savings, allowing users to receive fixed-interest rewards. Moreover, admins can access, modify, and initiate new savings programs with the presets page, effortlessly incorporating both business and client preferences.
The savings feature offers flexibility across the board, allowing users to set customised annual interest rates and adjust investment duration with 30-day intervals (30, 60, or 90 days). Brokers may also impose an early withdrawal penalty to maintain the viability of their savings plans.
The savings feature is highly customisable and configurable. The annual interest earnings option will motivate the clients to retain their funds within the broker’s ecosystem. Additionally, it enables brokers to increase fund retention and liquidity within B2Core, resulting in an advantageous situation for everybody involved.
Final Remarks
B2Core continues B2Broker’s mission to deliver quality across all products and services, ensuring maximum client satisfaction. The V2.1 update is another testament to raising industry standards!
The team is working on the complete transition of B2Core to the new interface. Additionally, B2Core intends to offer flexible interest rates for the savings plans. The team also works hard to add new integrations and expansions, allowing clients to enjoy a comprehensive CRM and back-office solutions suite!
Explore B2Core’s new features today and discover the benefits for your business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404452158/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder28.4.2026 14:42:00 CEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 14:28:00 CEST | Press release
CTIBIOTECH™, a leading innovator in advanced human tissue engineering, proudly announces CTIONCOTEST™ platform is awarded Major Bpifrance Funding to Industrialize 3D Bioprinted Cancer Models CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the pla
BMG and Concord Combine to Create World’s Leading Independent Music Company28.4.2026 14:11:00 CEST | Press release
Creates global platform to deliver superior service to artists, songwriters, and partnersUnlocks meaningful value through greater scale and strong cash flow, enabling continued investment in music rights, creative talent, and technologyBob Valentine to serve as CEO and Thomas Coesfeld as Chairman of the combined company, with global headquarters in Nashville and European Headquarters in BerlinCombined company to be named BMG with divisions “BMG Publishing” and “Concord Records” BMG and Concord today announced a definitive agreement to combine their businesses, creating the leading independent music company in the world. Operating under the BMG name, the combined company will bring together two highly complementary businesses to establish a scaled, global company delivering superior service to artists, songwriters, and partners – firmly grounded in an independent, artist-first model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study28.4.2026 14:00:00 CEST | Press release
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and Disparities by Skin Pigmentation (NeoPODS) study findings were presented from the podium at the Pediatric Academic Society in Boston, MA on Monday, April 27th at 10 am EST by lead author Dr. Heather Siefkes on behalf of colleagues at the University of California, Davis and the University of Mississippi
KAYTUS AI Compute Pod Wins 2026 iF Design Award and Red Dot Award, Setting a New Standard for AI Data Center28.4.2026 11:54:00 CEST | Press release
Delivering up to 130kW of liquid cooling per rack, the solution synchronizes cooling output with IT load in real time within seconds, to support high-density AI, large-scale computing, and HPC deployments, while reducing build time by 70% KAYTUS, a leading provider in AI infrastructure and liquid-cooling solutions, announced that its AI Compute Pod has received both the 2026 iF Design Award and Red Dot Award. This dual recognition not only stems from its outstanding performance in green, low-energy operation—achieving up to 130 kW cooling capacity per rack and a PUE as low as 1.1 through optimized thermal and power design—but also from its innovative approach to intelligent control and efficient O&M. The solution enables second-level synchronization between cooling and IT workloads, and leverages a dual-group control strategy to improve cooling energy efficiency by over 10%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom